Table 2.
Overview of emerging medications targeting receptors related to itch and their modes of action.
| Target | Medication | Mode | Disease | References |
|---|---|---|---|---|
| MRGPRX4 | – | Antagonist | Cholestatic pruritus | – |
| NK1R |
Aprepitant Tradipitant |
Antagonist |
Atopic dermatitis Mycosisfungoides Sézary syndrome |
[171–173] |
| PAR2 | PZ-235 | Antagonist | Atopic dermatitis | [178] |
| TRPV1 | Asivatrep | Antagonist | Histamine-induced itch | [181, 182] |
| TRPV3 |
Coumarin osthole Citrusinine-II Alpha-Mangostin Isochlorogenic acid Dyclonine Trpvicin |
Antagonist |
Atopic dermatitis Olmsted syndrome Psoriasis |
[46, 183–188] |
| TRPV4 |
Crotamiton Vitexin |
Antagonist |
Atopic dermatitis Contact dermatitis Psoriasis |
[189, 190] |
| TRPM8 |
Cryosim-1 Borneol |
Agonist |
Chronic pruritus Urticaria |
[191–195] |
| CCR4 |
Mogamulizumab RPT193 |
Antagonist/Antibody |
Atopic dermatitis Psoriasis Sézary syndrome |
[199, 200] |
| OX40/OX40L |
Amlitelimab Rocatinlimab GBR830 KHK4083 |
Antibody |
Atopic dermatitis Psoriasis |
[205–209] |
| TSLP | Tezepelumab | Antibody | Atopic dermatitis | [212] |
| IL-31/IL-31R | Nemolizumab | Antibody | Atopic dermatitis | [214] |
| IL-13/IL-13R |
Lebrikizumab Tralokinumab |
Antibody | Atopic dermatitis | [215, 216] |
| IL-4/IL-4R | Dupilumab | Antibody | Atopic dermatitis | [217] |
| IL-17/IL-17R | Secukinumab | Antibody | Psoriasis | [219] |
| IL-23/IL-23R | Guselkumab | Antibody | Psoriasis | [220] |
| TYK2 | Deucravacitinib | Inhibitor | Psoriasis | [222] |
| RORγt | JNJ-61803534 | Agonist | Psoriasis | [223] |